An insider look at Trebla over the months
MOST RECENT POSTS FROM THE TREBLA TEAM TO YOU
Here at Trebla we love to keep our clients updated and involved.
It is important to us that our clients are aware of changes in the pharmaceutical space and opportunities that may arise. That’s why we decided to create our monthly newsletter, The Trebla Times, where all that and more can be found.
Make sure to check it out!
March 2026
March brought the momentum the market has been building toward. After a slow start to the year, biotech is finally starting to defrost. M&A activity is picking up, hiring remains active across clinical and regulatory functions, and investors are re-engaging.
At Trebla, we felt that shift firsthand with new partnerships, continued growth, and a strong pipeline of talent.
February 2026
February is the month of love, which means everyone is searching for “the one.” In biotech, that looks like the Regulatory leader who has shepherded approvals, the Clinical physician who has delivered pivotal studies, and the Safety MD who keeps programs on track and risk contained.
The catch? They’re not waiting around. February’s market is moving quickly, and the strongest matches are getting secured early.